ProCE Banner Activity

How the Multifactorial Nature of NASH May Affect Treatment

Clinical Thought
No therapies are FDA approved for NASH, but I believe metabolic, inflammatory, and fibrotic aspects of NASH will all shape its management.

Released: October 04, 2019

Expiration: October 02, 2020

Share

Faculty

Manal F. Abdelmalek

Manal F. Abdelmalek, MD, MPH

Professor of Medicine
Division of Gastroenterology and Hepatology
Duke University
Durham, North Carolina

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Manal F. Abdelmalek, MD, MPH

Professor of Medicine
Division of Gastroenterology and Hepatology
Duke University
Durham, North Carolina

Manal F. Abdelmalek, MD, MPH, has disclosed that she has received consulting fees from Bristol-Myers Squibb, NGM Pharma, Prometic, and TaiwanJ; funds for research support from Allergan, Bristol-Myers Squibb, Galmed, Genfit, Gilead Sciences, Intercept, Madrigal, NGM Biopharma, Novartis, and TaiwanJ; and fees for non-CME/CE services from Genfit and Intercept.